How FDA Rules Impact Supplier Cybersecurity
Post Summary
Medical device cybersecurity is no longer optional - it’s mandatory under updated FDA regulations.
New rules like Section 524B of the FD&C Act and the Quality Management System Regulation (QMSR) require manufacturers to monitor cybersecurity risks across their entire supply chain. This includes tracking third-party components, cloud services, and software libraries. Non-compliance can result in rejected premarket submissions or enforcement actions.
Key takeaways:
- Software Bill of Materials (SBOM): Manufacturers must maintain and update a detailed SBOM for all device components.
- Supplier Oversight: Vendors must meet strict cybersecurity standards, with contracts specifying response times for vulnerabilities.
- Secure Development Frameworks: Required for managing risks in third-party software and ensuring lifecycle security.
- Incident Response: Suppliers need formal systems for vulnerability monitoring, disclosure, and patch management.
The FDA’s approach integrates cybersecurity into quality systems, making it a shared responsibility between manufacturers and suppliers. Neglecting these requirements could delay market access or compromise patient safety.
FDA Medical Device Cybersecurity Compliance Requirements for Suppliers
FDA cybersecurity requirements: What is surprising and new in 2026?
sbb-itb-535baee
FDA Cybersecurity Guidance and Recent Changes
The FDA has significantly revamped its approach to medical device cybersecurity over the past three years. These updates directly impact how manufacturers manage supplier risks throughout the entire product lifecycle. The changes expand the FDA's regulatory framework, placing greater emphasis on supplier cybersecurity responsibilities.
Section 524B of the FD&C Act Requirements
Building on earlier regulatory expansions, Section 524B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) introduces mandatory cybersecurity measures in supplier agreements. This shift elevates FDA cybersecurity guidance to a legal requirement.
The law explicitly connects "reasonable assurance of cybersecurity" to the safety and effectiveness of medical devices. To meet these standards, manufacturers must include Software Bill of Materials (SBOM) management in supplier agreements. This ensures that all software components - whether commercial, open-source, or off-the-shelf - are properly documented and tracked [2].
"Section 524B of the FFDCA requires that any device that meets the definition of a 'cyber device' provide certain cybersecurity information in the requisite premarket submission to ensure that the device meets the FFDCA's cybersecurity requirements." – Ariel Z. Seeley, Of Counsel, Morgan Lewis [2]
Additionally, Section 301(q) of the FD&C Act makes the failure to maintain cybersecurity procedures a prohibited act [2]. This means the FDA now has the authority to deny premarket authorization solely due to cybersecurity shortcomings if submissions fail to comply with Section 524B [2].
June 2025 FDA Final Guidance Updates
On June 27, 2025, the FDA released its final guidance titled "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions" [1]. This document replaced all prior cybersecurity guidance, establishing comprehensive recommendations for device design, labeling, and documentation in premarket submissions [1].
A key update was the incorporation of Section 524B requirements into the FDA's quality system expectations [1]. The guidance emphasizes continuous cybersecurity oversight throughout the device lifecycle, requiring manufacturers to implement ongoing vulnerability monitoring and dependable patch management as part of their quality systems.
The updated guidance also clarified terms for supplier agreements, mandating that SBOMs be easily produced and updated as devices evolve [2]. However, it does not address how manufacturers should handle legacy devices - older systems that cannot be patched. For these products, the FDA suggests initiating early discussions to explore compliance options [2].
Cyber Device Definitions and Premarket Submissions
The FDA defines a "cyber device" as any device that meets three criteria: it includes software validated, installed, or authorized by the sponsor; it can connect to the internet; and it has features vulnerable to cyber threats [3]. This broad definition applies even if the device is not currently network-enabled.
Under Section 524B(b), sponsors must include three key elements in their premarket submissions:
- A plan to monitor, identify, and address postmarket vulnerabilities within a reasonable timeframe.
- Processes and procedures to ensure cybersecurity, including updates and patches.
- A complete SBOM listing all commercial, open-source, and off-the-shelf software components [3].
As of October 1, 2023, most 510(k) submissions must use the eSTAR electronic template. Submissions lacking accurate responses or necessary cybersecurity attachments will be placed on a Technical Screening hold [3]. These requirements apply to all submission pathways, including 510(k), PMA, De Novo, and HDE, along with their supplements [3].
For manufacturers unsure whether their device qualifies as a cyber device, the FDA encourages direct consultation. Additionally, any device modifications requiring new premarket review must comply with current Section 524B requirements, even if the original device was authorized under earlier rules [3].
FDA Expectations for Supplier Cybersecurity
The FDA now views supplier cybersecurity as a fundamental part of quality management, not just an optional feature. Manufacturers are responsible for ensuring that every third-party component - whether it's cloud services or open-source libraries - meets strict security standards throughout a device's lifecycle. Cybersecurity is now built into purchasing controls and design verification processes.
Secure Product Development Framework (SPDF) Integration
Manufacturers are required to adopt a Secure Product Development Framework (SPDF) that extends across the entire supply chain. This ensures third-party components are both developed and maintained securely. Starting February 2, 2026, the SPDF must align with ISO 13485 purchasing controls (Clause 7.4) under the Quality Management System Regulation (QMSR) to assess and monitor suppliers critical to cybersecurity.
The framework should include thorough threat modeling to address risks posed by third-party components, cloud services, and communication interfaces. Security testing - such as penetration testing, vulnerability scanning, and fuzz testing - must encompass the entire device system, including third-party code. Additionally, manufacturers are expected to maintain a machine-readable Software Bill of Materials (SBOM) in formats like SPDX or CycloneDX. This SBOM should document all third-party and open-source components across the product lifecycle.
These measures integrate cybersecurity directly into the design process, laying the groundwork for stringent compliance and verification, as discussed in later sections.
Compliance with 21 CFR 820.50
Under 21 CFR 820.50, manufacturers must establish clear procedures to ensure that all purchased products and services - including software and cloud services - adhere to specific cybersecurity requirements. The regulation states:
"Each manufacturer shall establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements." - 21 CFR 820.50 [4]
This means supplier selection can't rely solely on functional performance. Manufacturers must also assess whether suppliers provide secure code, maintain an SPDF, and offer ongoing security patch support.
Formal agreements with suppliers are essential. These contracts should define clear terms, such as mandatory timelines for vulnerability notifications - typically within 72 hours for critical issues - and provisions for timely security updates. Manufacturers should also specify the duration of security support to avoid devices becoming unpatchable during their clinical use.
| Vendor Classification Tier | Criteria | Assessment Frequency |
|---|---|---|
| Critical | Direct access to patient data or safety-critical software | Quarterly |
| High | Indirect access to device systems or known vulnerability history | Semi-annually |
| Medium | Peripheral components with limited interaction | Annually |
| Low | No network connectivity or data access | At onboarding |
Verifying Supplier Cybersecurity in Device Design
Beyond supplier evaluations, manufacturers must ensure that third-party components integrate securely into the device's design. These components should meet the device's overall security architecture requirements, ensuring no weak links are introduced. By February 2026, all cybersecurity documentation must be generated through established Quality Management System (QMS) processes instead of being treated as standalone appendices.
Cybersecurity requirements for third-party components must be part of design inputs (ISO 13485 Subclause 7.3.3) before incorporating these components into the device. Verification procedures (Clause 7.4.3) require manufacturers to confirm compliance through activities like vulnerability scanning, penetration testing, and SBOM validation. These efforts support the continuous risk management process outlined in the SPDF.
"The rules of the game have changed. Manufacturers that treat cybersecurity as a documentation exercise rather than a design discipline are receiving multi-page deficiency letters that delay market authorization." - Naomi Schwartz, VP of Regulatory Strategy, Medcrypt [5]
Manufacturers should evaluate suppliers based on recognized certifications, such as ISO 27001, SOC 2 Type II, or IEC 62443, and require evidence of secure development practices. The SBOM should be continuously updated and monitored using automated tools to identify new vulnerabilities. For legacy devices where suppliers no longer provide patches, manufacturers should implement compensating controls, like network segmentation, and document lifecycle transition plans.
Incident Response and Notification Protocols
Suppliers are expected to incorporate incident response into their cybersecurity strategies. According to Section 524B of the FD&C Act, they are legally required to monitor, identify, and address vulnerabilities that arise after a product has entered the market [4]. This means having formal systems in place to quickly detect, assess, and respond to potential security threats.
Supplier Vulnerability Monitoring Requirements
In addition to maintaining a detailed SBOM (Software Bill of Materials) and conducting ongoing supplier monitoring, suppliers must implement a Coordinated Vulnerability Disclosure (CVD) process. This process involves continuously scanning all third-party components listed in the SBOM for known vulnerabilities (CVEs) [4].
"A manufacturer's postmarket cybersecurity program should include a process for the intake and handling of vulnerability reports, such as through the use of a Coordinated Vulnerability Disclosure (CVD) process." - FDA [4]
To prioritize responses, suppliers should rely on the Common Vulnerability Scoring System (CVSS). This system helps objectively measure the severity of vulnerabilities, ensuring critical issues are addressed immediately while less urgent problems follow a standard update schedule. Once vulnerabilities are identified, having a structured approach to patch management becomes essential.
Patch Management and Update Requirements
The FDA makes a clear distinction between permanent fixes (remediation) and temporary measures (mitigation). As part of their incident response plans, suppliers must account for both approaches [4]. Security updates that improve a device's cybersecurity do not need to be reported under 21 CFR part 806. However, urgent patches that address critical safety risks must be acted upon immediately and properly documented.
"FDA recommends that manufacturers provide a plan for how they will identify and address postmarket vulnerabilities, including through the use of a Software Bill of Materials (SBOM)." - FDA [4]
To ensure clarity and efficiency, suppliers should create patching tiers. These tiers differentiate between routine updates and urgent patches, offering manufacturers confidence that devices and their connected systems remain secure throughout their lifecycle.
FDA Enforcement Actions for Cybersecurity Violations
A robust incident response plan does more than just protect devices - it also helps suppliers avoid regulatory penalties. Under Section 524B, the FDA holds the authority to enforce cybersecurity requirements. For example, premarket submissions that fail to include adequate cybersecurity plans or SBOMs may receive a "Refuse to Accept" (RTA) decision, effectively preventing the product from entering the market [4]. This highlights the critical role of incident response as part of a supplier's broader cybersecurity framework.
For streamlined vulnerability monitoring and incident response, consider leveraging platforms like Censinet RiskOps™ (https://censinet.com).
Conclusion
The FDA now requires medical device manufacturers and their suppliers to prioritize cybersecurity across the entire supply chain. Under Section 524B of the FD&C Act, cybersecurity is no longer just a recommendation - it's a mandatory aspect of working with device manufacturers. Suppliers must integrate cybersecurity measures during product development and remain vigilant about vulnerabilities throughout the device's lifecycle.
This regulatory update means suppliers need to act swiftly to align their practices. Lifecycle-based cybersecurity measures, such as Coordinated Vulnerability Disclosure processes, automated vulnerability scanning, and well-defined contractual obligations, are essential. Failing to implement these measures not only risks enforcement actions but could also delay market access.
"Cybersecurity is a shared responsibility among stakeholders, including health care facilities, patients, providers, and manufacturers." - FDA [4]
Adopting these practices is essential for meeting FDA standards. Compliance with 21 CFR 820.50 and the Secure Product Development Framework ensures both the security of medical devices and the protection of patient data. By embedding cybersecurity into their Quality Management Systems, suppliers can establish themselves as reliable partners, avoid regulatory penalties, and, most importantly, uphold patient safety.
Healthcare organizations looking to effectively manage third-party risk and ensure supplier compliance can turn to Censinet RiskOps™ (https://censinet.com) for support throughout the device lifecycle.
FAQs
Does my product qualify as an FDA “cyber device”?
If your product is considered an FDA "cyber device", it means it’s a medical device with software or hardware vulnerabilities that could potentially impact patient safety or the device’s performance. This classification is particularly relevant if the device is subject to the FDA's cybersecurity regulations and guidelines, which are designed to address these risks and ensure both patient safety and reliable device functionality.
What SBOM format and update cadence will FDA expect from suppliers?
The FDA now mandates that suppliers include Software Bill of Materials (SBOMs) in their regulatory submissions. These SBOMs must also be updated regularly throughout the device's lifecycle to account for patches and vulnerabilities. To meet these standards, SBOMs must adhere to the NTIA's minimum attributes, which include:
- Component name and version
- Unique identifiers
- Dependency relationships
- Support level
- Timestamps
This enforcement officially started on October 1, 2023.
What proof of incident response and patching will suppliers need to provide?
Suppliers are required to submit detailed documentation of their incident response plans. This should outline the specific steps they take for detecting, analyzing, containing, and reporting cybersecurity incidents. Additionally, they must provide proof of timely patching and vulnerability management. This includes records of deployed patches, Software Bill of Materials (SBOMs), and risk assessments, ensuring compliance with FDA cybersecurity standards.
